Aura Biosciences, Inc. Comprehensive Income
Aura Biosciences, Inc. (AURA) reported Comprehensive Income of -$46.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-11
- Aura Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$46.10M.
- Aura Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$33.79M.
- Aura Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$25.73M.
- Aura Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$26.09M.
- Aura Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$106.56M.
- Aura Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$87.19M.
- Aura Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$75.80M.
- Aura Biosciences, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$58.84M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$46.10M 10-Q · filed 2026-08-11 | -$79.89M 10-Q · filed 2026-08-11 | -$105.62M derived: sum of 3 quarters · filed 2026-08-11 | -$131.71M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$33.79M 10-Q · filed 2026-05-11 | -$59.52M derived: sum of 2 quarters · filed 2026-05-11 | -$85.61M derived: sum of 3 quarters · filed 2026-05-11 | -$112.70M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$25.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$51.82M derived: sum of 2 quarters · filed 2026-03-30 | -$78.92M derived: sum of 3 quarters · filed 2026-08-11 | -$106.56M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$26.09M 10-Q · filed 2025-11-13 | -$53.19M derived: sum of 2 quarters · filed 2026-08-11 | -$80.83M 10-Q · filed 2025-11-13 | -$107.00M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$27.10M 10-Q · filed 2026-08-11 | -$54.74M 10-Q · filed 2026-08-11 | -$80.92M derived: sum of 3 quarters · filed 2026-08-11 | -$101.17M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$27.64M 10-Q · filed 2026-05-11 | -$53.82M derived: sum of 2 quarters · filed 2026-05-11 | -$74.07M derived: sum of 3 quarters · filed 2026-05-11 | -$94.61M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$26.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$46.43M derived: sum of 2 quarters · filed 2026-03-30 | -$66.97M derived: sum of 3 quarters · filed 2026-03-30 | -$87.19M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$20.25M 10-Q · filed 2025-11-13 | -$40.79M derived: sum of 2 quarters · filed 2025-11-13 | -$61.02M 10-Q · filed 2025-11-13 | -$82.47M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$20.54M 10-Q · filed 2025-08-13 | -$40.77M 10-Q · filed 2025-08-13 | -$62.22M derived: sum of 3 quarters · filed 2025-08-13 | -$80.65M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$20.23M 10-Q · filed 2025-05-15 | -$41.69M derived: sum of 2 quarters · filed 2025-05-15 | -$60.11M derived: sum of 3 quarters · filed 2025-05-15 | -$78.58M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$21.46M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$39.88M derived: sum of 2 quarters · filed 2025-03-24 | -$58.36M derived: sum of 3 quarters · filed 2025-03-24 | -$75.80M 10-K · filed 2025-03-24 |
| 2023-09-30 | -$18.42M 10-Q · filed 2024-11-12 | -$36.90M derived: sum of 2 quarters · filed 2024-11-12 | -$54.34M 10-Q · filed 2024-11-12 | -$70.82M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$18.48M 10-Q · filed 2024-08-08 | -$35.92M 10-Q · filed 2024-08-08 | -$52.40M derived: sum of 3 quarters · filed 2024-08-08 | -$68.32M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$17.44M 10-Q · filed 2024-05-09 | -$33.92M derived: sum of 2 quarters · filed 2024-05-09 | -$49.84M derived: sum of 3 quarters · filed 2024-05-09 | -$63.43M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$16.48M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | -$32.40M derived: sum of 2 quarters · filed 2024-03-27 | -$45.99M derived: sum of 3 quarters · filed 2024-03-27 | -$58.84M 10-K · filed 2024-03-27 |
| 2022-09-30 | -$15.92M 10-Q · filed 2023-11-09 | -$29.51M derived: sum of 2 quarters · filed 2023-11-09 | -$42.35M 10-Q · filed 2023-11-09 | -$53.98M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$13.59M 10-Q · filed 2023-08-09 | -$26.43M 10-Q · filed 2023-08-09 | -$38.06M derived: sum of 3 quarters · filed 2023-08-09 | -$46.90M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$12.84M 10-Q · filed 2023-05-11 | -$24.47M derived: sum of 2 quarters · filed 2023-05-11 | -$33.31M derived: sum of 3 quarters · filed 2023-05-11 | -$42.16M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$11.63M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$20.47M derived: sum of 2 quarters · filed 2023-03-15 | -$29.32M derived: sum of 3 quarters · filed 2023-03-15 | -$35.25M 10-K · filed 2023-03-15 |
| 2021-09-30 | -$8.84M 10-Q · filed 2022-11-10 | -$17.69M derived: sum of 2 quarters · filed 2022-11-10 | -$23.62M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | -$8.85M 10-Q · filed 2022-08-11 | -$14.78M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | -$8.26M 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |